Levy Elliott M. 4

What Happened

• Elliott M. Levy, a director of Editas Medicine (EDIT), was granted a derivative award covering 51,700 shares on June 17, 2026. The Form 4 reports the acquisition as a derivative security at $0.00 per share (total reported value $0). A footnote states the option is scheduled to vest in full on June 17, 2027.

Key Details

• Transaction date: June 17, 2026; Form 4 filed: June 22, 2026 (filed later than the standard 2-business-day window).
• Reported price: $0.00 per share in the filing (common for option grants reported as derivative awards).
• Vesting: Scheduled to vest in full on June 17, 2027 (per footnote).
• Shares owned after transaction: Not specified in the provided filing summary.
• 10b5-1/other plans or tax withholding: None disclosed in the provided details.
• Timeliness: Filing appears late relative to the SEC’s usual 2-business-day Form 4 deadline (may have reporting implications).

Context

• This transaction is a grant of a derivative security (an option award) rather than an immediate stock purchase. The award vests in one year, so it does not represent immediate acquisitions of common shares. Grants to directors are commonly part of routine compensation; the filing itself does not state motivation or indicate immediate market action.